Jamie Robyn

Author PubWeight™ 8.50^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.	Blood	2003	1.37
2	KIT D816V-associated systemic mastocytosis with eosinophilia and FIP1L1/PDGFRA-associated chronic eosinophilic leukemia are distinct entities.	J Allergy Clin Immunol	2007	1.33
3	HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome.	Blood	2002	1.19
4	Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis.	Haematologica	2010	1.19
5	Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.	Blood	2007	1.00
6	Activity of imatinib in systemic mastocytosis with chronic basophilic leukemia and a PRKG2-PDGFRB fusion.	Haematologica	2008	0.96
7	Treatment of systemic mastocytosis.	Immunol Allergy Clin North Am	2006	0.76
8	Imatinib-responsive hypereosinophilic syndrome.	Leuk Res	2006	0.75